Retatrutide + Follistatin Blend
A single prefilled pen pairing the triple-agonist Retatrutide with Follistatin — formulated for research protocols focused on fat reduction while preserving lean mass. Research use only.
The pen ships sealed and pre-dosed. Dial, inject, store refrigerated. No reconstitution, no transfer loss, no volume calculation.
- No reconstitution. Skip bac water, syringes, swirl-and-wait.
- 0.1 mg dose resolution. Mechanical counter, not syringe-barrel guessing.
- Sealed single cartridge. No rubber septum re-entries, no exposed plunger.
- Package-to-dose < 60 s. Pull cap, dial, record. No prep workflow.
- The triple-agonist metabolic component (Retatrutide: GLP-1 / GIP / glucagon)
- Follistatin's myostatin-antagonism, studied for lean-mass retention
- Researched as a “fat-down, muscle-spared” stack, addressing the lean-mass loss discussed in aggressive GLP-1 protocols
Areas of laboratory and preclinical research only. Not a description of effects in humans. Research use only — not for human or animal consumption.
- Total mass
- 30 mg
- Volume
- 3 ml
- Concentration
- 10.00 mg / ml
- Format
- Prefilled penReady to use — no reconstitution, no BAC water, no syringe calculation
- Dose increment
- 0.1 mgDial-click precision
- Storage
- 2–8 °C refrigeratedDo not freeze
- Manufacturing
- EU cGMP facilityReleased against pre-registered specs
All products are intended for laboratory research use only. Not for human or animal consumption, diagnostic, or therapeutic use.
Commonly studied with Reta+FST
Retatrutide
Reta- Dose
- 30 mg
- Purity
- —
- € / mg
- €8.97/mg
Triple GIP/GLP-1/glucagon receptor agonist research peptide — the most-anticipated next-generation metabolic compound, in a Vivaprime prefilled pen.
AOD-9604
AOD- Dose
- 30 mg
- Purity
- —
- € / mg
- €6.63/mg
Modified hGH fragment 176–191 research peptide — widely studied in adipose-tissue and lipolytic-pathway research, in a Vivaprime prefilled pen.
5-Amino-1MQ
- Dose
- 100 mg
- Purity
- —
- € / mg
- €2.29/mg
5-Amino-1MQ small-molecule NNMT-pathway inhibitor research compound — complements NAD+-salvage research. Vivaprime prefilled pen.
Adipotide
- Dose
- 30 mg
- Purity
- —
- € / mg
- €7.97/mg
Experimental pro-apoptotic peptide studied for its selective action on the vasculature supplying white adipose tissue. Prefilled in a ready-to-use pen for research use only.
Quick answers about Reta+FST
- Is Reta+FST pre-mixed and ready to use, or do I need to reconstitute it?
- Retatrutide + Follistatin Blend ships as a sealed prefilled pen. No reconstitution, no bacteriostatic water, no syringe draw. Each pen is pre-dosed with dial-click increments at the factory under EU cGMP release specifications.
- How is Reta+FST tested and what's on the Certificate of Analysis?
- Every batch is released against a written specification. Identity is confirmed by HPLC-MS plus Amino Acid Analysis; purity is measured by reverse-phase HPLC; residual solvents per ICH Q3C; endotoxin (LAL) per USP. The latest batch and its % purity are published on the product page. Full COA history is available on our lab results page.
- How should Reta+FST be stored?
- Refrigerate 2–8 °C. Do not freeze. Protect from light. Refer to the label for the in-use stability window.
- How is Reta+FST shipped?
- Cold-chain shipped from within the EU with ice packs and insulated packaging. Orders ship within 1 business day and most EU addresses arrive in 2–4 business days. Orders over €300 ship free.
- Is Reta+FST sold for human use?
- No. Retatrutide + Follistatin Blend is sold strictly for in vitro research and laboratory use by qualified professionals. It is not intended for human consumption, therapeutic, or diagnostic use. This research-use framing is enforced in all product materials and operational documentation.
- How many doses does a 30 mg + 1.2 mg / 3 ml pen pen of Reta+FST deliver?
- The exact number of doses depends on the research protocol's per-dose quantity. Pens dial in 0.1 mg increments and total mass per pen is shown on the product page. Divide total mass by your planned per-dose mass to estimate doses.